Intravascular Ultrasound Section is Supported by Volcano Corporation
PatientCenter
VascularTherapy.OrgBlogDiscussion Forum
Home » IVUS Center » IVUS News » May 7, 2007

Volcano Corporation Reports
49 Percent Increase in Revenues

IVUS Disposable Sales Increase 33 Percent


May 7, 2007 -- RANCHO CORDOVA, Calif. -- Volcano Corporation (Nasdaq: VOLC), a leading provider of intravascular ultrasound (IVUS) and functional measurement (FM) products designed to enhance the diagnosis and treatment of vascular and structural heart diseases, today reported that revenues in the first quarter of 2007 increased 49 percent over revenues in the first quarter a year ago.

For the quarter ended March 31, 2007, Volcano reported record revenues of $29.6 million compared with revenues of $19.9 million in the first quarter of 2006. The company said its financial performance was driven by a 33 percent increase in IVUS disposable revenues versus the first quarter of the prior year.

Volcano reported its third consecutive quarter of profitability on a GAAP basis, with net income of $1.7 million, or $0.04 per diluted share, versus a net loss of $6.4 million, or $0.93 per share, in the first quarter a year ago. The company recorded stock-based compensation expense of $1.2 million, versus $689,000 in the same quarter a year ago. Excluding stock-based compensation expense, Volcano recorded net income of $2.9 million, or $0.07 per diluted share, versus a net loss of $5.7 million, or $0.83 per share, in the first quarter of 2006. Weighted-average diluted shares outstanding were 41.7 million in the first quarter of 2007 versus 6.9 million a year ago. The increase reflects the conversion of preferred stock to common stock, the exercise of warrants and the company's equity offerings in June and December of last year. A reconciliation of the company's GAAP to non-GAAP results can be found in today's earnings news release on the company's website at www.volcanocorp.com.

"Volcano had an excellent quarter with strong revenue growth and significant accomplishments that support our long-term growth strategy, including major marketing agreements with leading industry partners. In addition, we saw the continued release of data that portrays the important role that IVUS can play in enhancing the safety and efficacy of stenting and other endovascular procedures," said Scott Huennekens, president and chief executive officer of Volcano.

During the quarter, Volcano announced two strategic transactions designed to support its growth objectives. They included a collaboration with Royal Philips Electronics in which the company's suite of s5i IVUS consoles will be compatible with Philips' Allura Xpder FD cath lab systems. In addition, Volcano and ev3 Inc. announced an exclusive U.S. distribution agreement under which Volcano will be selling ev3's Spider FX, a leading embolic protection device for use in stenting of saphenous vein grafts (SVG's).

"The Philips agreement is important because we are now partnering with another major cath lab equipment provider. The ability to integrate our IVUS technology into their cath lab offerings will enable IVUS to be integrated quickly and seamlessly. In addition, we now have the opportunity to create regional co-marketing agreements with Philips in the U.S., Japan and Europe. Volcano is the only IVUS and functional measurement company with partnerships and safety and compatibility testing verifications with the large angiography companies," Huennekens said.

"The ev3 agreement will not only facilitate the market opportunity for our core offerings, but it also provides another product that can leverage the strong presence of our sales force. Transactions such as these, along with our programs to create product differentiation, are key elements of our growth strategy," he added.

"In addition to the successful implementation of initiatives to increase our presence in current markets, we are also executing on our product development and clinical strategies designed to address future opportunities, including stent optimization, the use of IVUS in conjunction with diagnostic angiography, Intra-Cardiac Echo and vulnerable plaque and applications in the carotid and peripheral arteries," Huennekens noted.

Guidance for 2007
Volcano expects revenues of approximately $125.0 million, which compares to prior revenue guidance of approximately $120.0 million. The company continues to expect gross margin for the year will be 60-61 percent and operating expenses to be 67-69 percent of revenues, as the company intends to accelerate its plan to increase its sales force and to build out its infrastructure to support future growth. The company expects to report a net loss on a GAAP basis of approximately $0.14 per share, compared to prior guidance of $0.15 per share. Weighted average basic shares outstanding are expected to be approximately 38.3 million at year end. Excluding stock-based compensation, Volcano expects to report net income of approximately $0.04 per diluted share, versus prior guidance of $0.03 per diluted share, assuming weighted average diluted shares outstanding at year-end of approximately 41.9 million.

Conference Call
The company will hold a conference call today at 2 p.m. Pacific Daylight Time (5 p.m. Eastern Daylight Time). The teleconference can be accessed by calling (913) 312-1293, passcode 4758002, or via the company's website at www.volcanocorp.com Please dial in or access the website 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available until May 14, at (719) 457-0820, passcode 4758002, and via the company's website.

Volcano Corporation
Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) IVUS tissue characterization. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,600 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at www.volcanocorp.com

Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock- based compensation is a non-cash expense. In addition, our management uses results of operations before these certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial measures in accordance with GAAP.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's financial guidance for 2007, expectations and outcomes regarding current and potential collaborations with other companies, the impact of clinical and other technical data, the safety and efficacy of the company's products, the success and timing of product development and clinical trial programs, market development and product use, and regulatory approvals. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


                               VOLCANO CORPORATION
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (in thousands)
                                   (Unaudited)

                                                  March 31,        December 31
                                                    2007              2006
     Assets
     Current assets:
            Cash and cash equivalents              $54,385           $77,738
            Short term investments
             available for sale                     42,484            17,787
            Accounts receivable, net                22,725            21,575
            Inventories                             15,157            13,423
            Prepaid expenses and other
             current assets                          2,189             2,208
                     Total current assets          136,940           132,731
     Restricted cash                                   354               352
     Property and equipment, net                    10,043             9,333
     Intangible assets, net                         11,187            11,946
     Other non-current assets                          695               363
                                                  $159,219          $154,725

     Liabilities and Stockholders' Equity
     Current liabilities:
             Accounts payable                       $8,957            $8,209
             Accrued compensation                    6,203             5,993
             Accrued expenses and other
              current liabilities                    4,556             5,292
             Deferred revenues                       3,480             2,675
             Current maturities of long-
              term debt                              1,557             1,654
                     Total current liabilities      24,753            23,823
     Long-term debt                                     44                66
     Deferred license fee                            1,313             1,375
     Other                                             258               279
                     Total liabilities              26,368            25,543
     Stockholders' equity                          132,851           129,182
                                                  $159,219          $154,725


                               VOLCANO CORPORATION
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands, except per share data)
                                   (Unaudited)

                                                  Three Months Ended March 31,
                                                     2007              2006

     Revenues                                      $29,579           $19,872
     Cost of revenues                               10,865             8,220
     Gross profit                                   18,714            11,652
     Operating expenses:
       Selling, general and administrative          12,584            11,645
       Research and development                      4,688             4,553
       Amortization of intangibles                     786               774
         Total operating expenses                   18,058            16,972
     Operating income (loss)                           656            (5,320)
     Interest expense                                  (89)           (1,312)
     Interest and other income, net                  1,317               291
     Income (loss) before provision for income taxes 1,884            (6,341)
     Provision for income taxes                        210                33
     Net income (loss)                              $1,674           $(6,374)
     Net income (loss) per share - basic             $0.04            $(0.93)
     Net income (loss) per share - diluted           $0.04            $(0.93)
     Weighted-average shares outstanding
      - basic                                       37,964             6,891
     Weighted-average shares outstanding
      - diluted                                     41,685             6,891


                              VOLCANO CORPORATION
             RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
                     (in thousands, except per share data)
                                  (Unaudited)

                                             Three Months Ended March 2007
                                                      Stock-based
                                             GAAP     compensation   Non-GAAP
                                             results    expense      results

     Revenues                                $29,579         $-     $29,579
     Cost of revenues                         10,865       (112)     10,753
     Gross profit                             18,714        112      18,826
     Operating expenses:
         Selling, general and
          administrative                      12,584       (923)     11,661
         Research and development              4,688       (208)      4,480
         Amortization of intangibles             786          -         786
           Total operating expenses           18,058     (1,131)     16,927
     Operating income                            656      1,243       1,899
     Interest expense                            (89)         -         (89)
     Interest and other income, net            1,317          -       1,317
     Income before provision for income
      taxes                                    1,884      1,243       3,127
     Provision for income taxes                  210          -         210
     Net income                               $1,674     $1,243      $2,917
     Net income per share - basic              $0.04      $0.03       $0.08
     Net income per share - diluted            $0.04      $0.03       $0.07
     Weighted-average shares outstanding
      - basic                                 37,964                 37,964
     Weighted-average shares outstanding
      - diluted                               41,685                 41,685


                                               Three Months Ended March 2006
                                                        Stock-based
                                             GAAP       compensation  Non-GAAP
                                             results      expense     results

     Revenues                                 $19,872         $-      $19,872
     Cost of revenues                           8,220        (68)       8,152
     Gross profit                              11,652         68       11,720
     Operating expenses:
         Selling, general and
          administrative                       11,645       (506)      11,139
         Research and development               4,553       (115)       4,438
         Amortization of intangibles              774          -          774
           Total operating expenses            16,972       (621)      16,351
     Operating income (loss)                   (5,320)       689       (4,631)
     Interest expense                          (1,312)         -       (1,312)
     Interest and other income, net               291          -          291
     Income (loss) before provision for
      income taxes                             (6,341)       689       (5,652)
     Provision for income taxes                    33          -           33
     Net income (loss)                        $(6,374)      $689      $(5,685)
     Net income (loss) per share - basic       $(0.93)     $0.10       $(0.83)
     Net income (loss) per share - diluted     $(0.93)     $0.10       $(0.83)
     Weighted-average shares outstanding
      - basic                                   6,891                   6,891
     Weighted-average shares outstanding
      - diluted                                 6,891                   6,891

Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock- based compensation is a non-cash expense. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

                        VOLCANO CORPORATION
                                 REVENUE SUMMARY
                                  (in millions)
                                   (Unaudited)


                                                     Q1 '07            Q1 '06
    IVUS Systems:
     United States                                    $3.7              $0.7
     Japan                                             0.7               0.3
     Europe                                            0.8               0.5
     Rest of World                                     0.6               0.5
    Total IVUS Systems                                $5.8              $2.0

    IVUS Disposables:
     United States                                    $9.4              $7.6
     Japan                                             6.1               4.5
     Europe                                            3.2               2.1
     Rest of World                                     0.6               0.3
    Total IVUS Disposables                           $19.3             $14.5

    FM:
     United States                                    $1.6              $1.3
     Japan                                             0.7               0.5
     Europe                                            1.2               0.9
     Rest of World                                     0.2               0.1
    Total FM                                          $3.7              $2.8

    Other                                              0.8               0.6
         Total                                       $29.6             $19.9
Source: Volcano Corporation

(Disclaimer: external links to news, press releases and other timely information sources are provided as a service by Angioplasty.Org, which is not responsible for the content found on any external sites. Items marked with a ($$) indicate that the external site normally restricts viewing to paid subscribers. Other sites may require free registration.

Angioplasty.Org Home   PatientCenter


send comments & suggestions to "info at angioplasty dot org"
Read our Privacy statement.

Angioplasty.Org is an editorially independent informational health site
which has received unrestricted educational grants from
Medtronic plc, TCROSS NEWS, Toshiba America Medical Systems, Volcano Corporation, Terumo Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY

For more information, see About Us
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021